Bionano Announces Prototype for its Next Single Molecule Imaging System for OGM
We believe OGM provides the most comprehensive, reliable and cost-effective solution for detecting structural variations (SVs). OGM is a workflow comprised of four proprietary stages: (i) ultra-high molecular weight DNA isolation; (ii) sequence-specific DNA labeling; (iii) single molecule linearization & imaging; and (iv) data processing and analysis. The third stage creates the molecule images and sequence motif patterns that are used to reveal SVs. This stage also sets the limit on the number of samples that can be processed per day. The throughput of the current Saphyr system is designed for the volumes encountered by academic medical centers doing standard clinical research in genomics, but large reference laboratories and contract research organizations (CROs) with higher volumes require an instrument with higher throughput capabilities.
Compared to the Saphyr system, which images DNA at a rate of approximately
The new imaging system will also incorporate features designed to make high throughput workflows more flexible, allowing for data collection to start without needing to wait for multiple samples being available, enabling high-coverage cancer experiments to be run next to lower coverage constitutional experiments and the ability to prioritize samples to be run ahead of all others. This flexibility is expected to surpass that of peer sequencing systems, where getting this flexibility often means waiting for enough samples to fill a flow cell or paying a significant per sample premium to have a sample consume more of a consumable.
Prototype photos of the next single molecule imaging system for OGM will be made available on Bionano’s social media channels on
Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its
Forward-Looking Statements of
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, [timing for anticipated launch of the commercial system;] [whether Saphyr will remain available for purchase after the new system is released;] the anticipated performance of the new system and its anticipated features, as well as anticipated performance of the new system relative to competitor sequencing systems; and timing of advancements in the new system. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive products, technologies or improvements in existing technologies; a reduction in large reference laboratories and CROs seeking to bring OGM in-house; delays in the advancement and development of the prototype into a commercially available system; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the
+1 (858) 888-7610
+1 (858) 366-3243
+1 (503) 799-7520
Source: Bionano Genomics